Bivalirudin, Human

Bivalirudin is a specific and reversible direct thrombin inhibitor. Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.\n\nHuman Bivalirudin is a synthetic 20 amino acid peptide. MW: 2180 Daltons\n\nSequence (linear):\nPhe-Pro-Arg-Pro-Gly-Gly-Gly-Gly- Asp-Gly-Asp-Phe-Glu-Glu-Ile- Pro-Glu-Glu-Tyr-Leu\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280nm. \n2. Analysis by RP-HPLC.\n\nStorage and Stability: \nLyophilized powder may be stored at 4 degrees C for short-term only. Stable for 12 months at -20 degrees C. Reconstitute to nominal volume (see reconstitution instructions for peptides) and store at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.\n\n\n

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

B2102-50

Size

1mg

Form

Supplied as a lyophilized powder in manntiol, sodium hydroxide, pH 5.5. Reconstitute with sterile ddH2O, 0.1% BSA or HSA to a concentration of >100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: < 0.1ng/ug (IEU/ug) of Bivalirudin.

References

1. Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Schussler JM, Cameron CS, Donsky MS, Am J Cardiol 2004 Dec 1;94(11):1417-9 2. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Clayton SB, Acsell JR, Uber WE, Ann Thorac Surg 2004 Dec;78(6):2167-9 3. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Cohen DJ, Lincoff AM, Chen HL, Sarembock IJ, J Am Coll Cardiol 2004 Nov 2;44(9):1792-800 4. Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. Rha SW, Kuchulakanti PK, Cheneau E, Aggrey G, Am J Cardiol 2004 Oct 15;94(8):1047-50 5. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Rha SW, Kuchulakanti PK, Cheneau E, Pichard AD, Cardiovasc Radiat Med 2004 Apr-Jun;5(2):64-70 6. Visual compatibility of bivalirudin with selected drugs. Hartman CA, Faria CE, Am J Health Syst Pharm 2004 Sep 1;61(17):1774, 1776.